Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q1 2024 Earnings Conference
The following is a summary of the Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript:
以下是Acumen製藥公司（ABOS）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Acumen Pharmaceuticals reported cash and marketable securities worth approximately $297 million at the end of Q1 2024.
R&D expenses for the quarter rose to $12.4 million due to costs related to the ALTITUDE-AD trial.
The company's Q1 G&A expenses increased to $5.3 million due to increased headcount, resulting in an operational loss of $17.8 million for the quarter.
Acumen Pharmicals報告稱，截至2024年第一季度末，現金和有價證券價值約2.97億美元。
由於與ALTITUDE-AD試驗相關的成本，本季度的研發費用增至1,240萬美元。
由於員工人數的增加，該公司第一季度的併購支出增加到530萬美元，導致該季度的運營虧損爲1,780萬美元。
Business Progress:
業務進展：
The first patient has been dosed in the ALTITUDE-AD Phase II study, which trials the effectiveness and safety of sabirnetug.
Positive feedback has been received on the Phase I INTERCEPT results, particularly on patient biomarker improvements.
A Phase I study is planned for a subcutaneous formulation of sabirnetug, which should be launched in mid-2024.
The company has established a collaboration with Lonza for the manufacturing of sabirnetug, leveraging the latter's regulatory knowledge and global manufacturing network.
在ALTITUDE-AD II期研究中，第一位患者服用了劑量，該研究試驗了sabirnetug的有效性和安全性。
已收到有關I期INTERCEPT結果的積極反饋，特別是患者生物標誌物改善的反饋。
計劃對sabirnetug的皮下製劑進行一項I期研究，該製劑將於2024年中期啓動。
該公司已與Lonza建立了合作關係，利用後者的監管知識和全球製造網絡，生產sabirnetug。
More details: Acumen Pharmaceuticals IR
更多詳情： Acumen 製藥公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。